# ACI-24 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aci-24

> ACI-24, sponsored by AC Immune SA (ACIU): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ACI-24 |
| Codes | ACI-24 |
| Sponsor | AC Immune SA (ACIU) https://sec-api.dev/companies/aciu/catalysts |
| Indications | alzheimer's disease triggers milestone payment, as, [alzheimer's disease](https://sec-api.dev/indications/alzheimer-s-disease) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### late 2025: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-08-05, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010174): "Further interim results from Part 1 of the VacSYn trial of ACI-7104.056 are expected later this year, and the AD3 cohort in the ABATE trial of ACI-24.060 will reach 12 months of treatment around year end, with interim results thereafter." https://www.sec.gov/Archives/edgar/data/1651625/000155837025010174/aciu-20250630xex99d3.htm

### early 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-08-05, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010174): "Third Alzheimer's disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026" https://www.sec.gov/Archives/edgar/data/1651625/000155837025010174/aciu-20250630xex99d3.htm

### April 30, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1/2. Indication: Alzheimer's Disease triggers milestone payment, as.
- First seen 2026-04-30, last confirmed 2026-04-30.
- Press release filed with the SEC (EX-99) (accession 0000950103-26-006499): "Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today" https://www.sec.gov/Archives/edgar/data/1651625/000095010326006499/dp245995_ex9901.htm
- Press release filed with the SEC (EX-99) (accession 0000950103-26-006499): "As announced separately today, AC Immune has initiated the final cohort, AD4, in the ongoing Phase 1b/2 ABATE trial of ACI-24 to treat Alzheimer's Disease" https://www.sec.gov/Archives/edgar/data/1651625/000095010326006499/dp245995_ex9901.htm
- Press release filed with the SEC (EX-99) (accession 0000950103-26-006498): "ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it dosed the first patients in Cohort AD4 in the ongoing Phase 1b/2 ABATE trial." https://www.sec.gov/Archives/edgar/data/1651625/000095010326006498/dp245993_ex9901.htm

## Same indication

- [PMN310](https://sec-api.dev/pdufa/pmn310) (PMN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aci-24.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ACI-24 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aci-24

```bibtex
@misc{secapidev_pdufa_aci_24_20261116,
  title        = {ACI-24 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aci-24}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aci_24_20261116","title":"ACI-24 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aci-24","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
